Vidac Pharma Holding (STU:T9G) EPS (Basic) : €-0.03 (TTM As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Vidac Pharma Holding EPS (Basic)?

Vidac Pharma Holding's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was €-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.03.

Vidac Pharma Holding's EPS (Diluted) for the six months ended in Jun. 2024 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €-0.03.

Vidac Pharma Holding's EPS without NRI for the six months ended in Jun. 2024 was €-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was -0.03.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

Vidac Pharma Holding EPS (Basic) Historical Data

The historical data trend for Vidac Pharma Holding's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vidac Pharma Holding EPS (Basic) Chart

Vidac Pharma Holding Annual Data

Trend

Dec21

Dec22

Dec23

EPS (Basic)

-0.01

Vidac Pharma Holding Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EPS (Basic)	Get a 7-Day Free Trial			-0.01	-0.01	-0.01	-0.02	-0.01

Vidac Pharma Holding EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Vidac Pharma Holding's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-1.48	-	0)	/	52821.074
	=	-0.00

Vidac Pharma Holding's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-0.508	-	0)	/	54.334
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.03

Vidac Pharma Holding (STU:T9G) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Vidac Pharma Holding EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Vidac Pharma Holding's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Vidac Pharma Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vidac Pharma Holding PLC (STU:T9G) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Wenlock Road, 20-22, London, GBR, N1 7GU

Website

https://www.vidacpharma.com

Vidac Pharma Holding PLC is a clinical-stage biopharmaceutical company developing first-in-class oncologic and onco-dermatologic therapies. Its drug, VDA-1102, is at the clinical development stage as an ointment for patients with actinic keratosis, an early form of skin cancer, and in a separate trial for an indication of cutaneous T-cell lymphoma (CTCL). A second molecule, VDA-1275, with possible application for a wide range of solid tumors.

Vidac Pharma Holding Headlines

No Headlines